Home/Filings/4/0001127602-23-026187
4//SEC Filing

DeLong Mark Jeffrey 4

Accession 0001127602-23-026187

CIK 0001492422other

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 4:18 PM ET

Size

4.5 KB

Accession

0001127602-23-026187

Insider Transaction Report

Form 4
Period: 2023-10-23
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
  • Sale

    Common Stock

    2023-10-23$46.04/sh131$6,03151,622 total
Footnotes (2)
  • [F1]This represents shares sold to cover tax withholding on a Restricted Stock Unit release.
  • [F2]This includes 412 shares from 04/30/2023 ESPP purchase.

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1
  • filerCIK 0001856078

Filing Metadata

Form type
4
Filed
Oct 23, 8:00 PM ET
Accepted
Oct 24, 4:18 PM ET
Size
4.5 KB